New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries  

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto^® Respimat^® (tiotropium/olodaterol) in first European countries^†. Spiolto^® Respimat^® is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Approvals of the treatment in other European countries are expected to follow in the coming months. Spiolto^® Respimat^® provides significant improvements in lung function, breathlessness, quality of life and rescue medication use over Spiriva^® right from the initial stages when patients need maintenance therapy.¹ These additional benefits could enable patients to remain active and avoid the downward spiral of COPD for as long as possible.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150701006479/en/

COPD is a chronic, progressive, treatable but incurable lung disease that affects 210 million people worldwide⁴ and is predicted to become the 3^rd leading cause of death by 2030.⁵ Patients are typically diagnosed when lung function is already significantly impaired and maintenance therapy is needed.⁶ They suffer from symptoms including breathlessness and coughing that often stop them from being active. This can lead to a downward spiral of worsening symptoms and even further inactivity,⁷ contributing to an increased risk of disability and death.⁸

“The additional benefits gained from Spiolto^® Respimat^® compared to Spiriva^® are significant for patients and data show the lung function benefits are even greater when used in the initial stages of COPD. It is a promising new therapeutic advance in COPD,” said Roland Buhl, Professor of Medicine and Head of the Pulmonary Department at Mainz University Hospital. “Optimal management right from the start of maintenance therapy may give patients with this highly debilitating lung disease, the best opportunity to stay active, manage their symptoms and have a better quality of life.”

The national regulatory approvals, following finalisation of the decentralised European regulatory procedure on 20^th May, are based on data from the >5,000 patient TONADO^® 1&2 clinical trials. The TONADO^® trials are part of the >15,000 patient TOviTO^® clinical trial programme which shows Spiolto^® Respimat^® provides clinically relevant improvements over Spiriva^®ǂ:

• Significant improvement in lung function^*, with greatest benefit seen in patients who are at the first stage of needing maintenance therapy for their COPD³ – and more than double the improvement in lung function^* in patients who had no prior maintenance therapy^§ (148ml vs. 72ml)²

• Reduction in breathlessness and less use of rescue medication among patients¹ (22% and 26% improvement in use of daytime and night-time rescue medication over Spiriva^® respectively)
• More patients experiencing noticeable improvements in their quality of life (57.5% vs 48.7%)¹
• Spiolto^® Respimat^® was well tolerated with a safety profile that was similar to tiotropium or olodaterol alone¹

“Since its first launch in 2002, Spiriva^® has brought medical benefits that have made a real difference to the lives of millions of patients with COPD around the world. Spiolto^® Respimat^® is our newest advance in COPD treatment. Its recent approval in the US^**, Canada and Australia, alongside the approval in countries across Europe, is an important step forward in our ongoing commitment to provide effective solutions for patients with COPD,” said Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “We anticipate further approvals of Spiolto^® Respimat^® in other European countries over the coming months.”

Spiolto^® Respimat^® is built on tiotropium, the active ingredient in Spiriva^® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.⁹ It is enhanced by olodaterol^††, a unique and effective long-acting beta2-agonist with a fast onset of action, specifically designed to complement the efficacy of Spiriva^®. Spiolto^® is delivered by Respimat^®, the only inhaler available that actively^ǂǂ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.^10-16

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/02_july_2015_copd.html

^* Improvement in trough FEV₁ after 24 weeks of treatment

^†As of Monday 29th June, Spiolto^® Respimat^® has been approved in Croatia, United Kingdom, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain

^ǂ The data in this press release refer to Spiolto^® Respimat^® 5/5µg dose which is the dose approved by regulatory authorities

^§ Patients without prior maintenance therapy at baseline

^** Registered as Stiolto^™ Respimat^® in the US

^†† Marketed as Striverdi^® Respimat^®

^ǂǂ Respimat^® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006479/en/

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs, +49 151 6894 7444
Fax: +49 (6132) 77 6601
press@boehringer-ingelheim.com
or
More information
www.boehringer-ingelheim.com